Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

FDA warns of safety risks in Pfizer’s postmarketing trial of Xeljanz

Pfizer designed Xeljanz as a Janus kinase (JAK) inhibitor. Creit: Jenix89.



  • FDA warns of safety risks in Pfizer’s postmarketing trial of Xeljanz

Go Top